Gastrointestinal Cancer
From the Journals
Colonoscopy lowers CRC risk and death, but not by much: NordICC
In an intention-to-screen analysis, 10-year results from the NordICC trial show that colonoscopy reduces the risk of colorectal cancer by only 18...
From the Journals
Colonoscopy in FIT-based screening demands higher ADR
Endoscopists performing colonoscopy in FIT-positive adults should aim for markedly higher ADRs compared with primary colonoscopy screening,...
From the Journals
AI tool may improve prediction of colorectal cancer recurrence
The QuantCRC algorithm can identify subsets of patients with colorectal cancer who may not need chemotherapy and who may need more intensive...
From the Journals
AGA Clinical Practice Update: Expert review of management of subepithelial lesions
SELs represent a heterogeneous group of lesions such as ectopic pancreatic tissue and tumors, and choice of management depends on several...
From the Journals
Is early-onset cancer an emerging global epidemic?
“This paper ... brings to light the importance of correctable lifestyle habits that may slow the rise of early onset cancers.”
News from the FDA/CDC
FDA approves futibatinib (Lytgobi) for certain biliary tract cancers
Futibatinib is “a key example of the potential of precision medicine” in intrahepatic cholangiocarcinoma.
From the Journals
Risk-adapted screening strategy could reduce colonoscopy use
In countries with limited health care resources, risk-adapted screening strategies could be more cost effective and accessible.
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.
Latest News
Could your patients benefit? New trials in noncolorectal GI cancer
Several new trials have launched.
From the Journals
Despite benefits, extended-interval pembro uptake remains low
It’s possible that low uptake could stem from clinicians’ doubts about switching to an extended-interval dose, given that the FDA’s approval was...
News
FDA OKs selpercatinib for adults with RET-fusion+ solid tumors
In 2020, selpercatinib received accelerated approval for lung and thyroid RET-positive tumors.